
    
      This is a phase 1, single-center, randomized, double-blind, two-way crossover study employing
      Abcertin and EU-sourced Cerezyme in healthy volunteers between the ages of 18 and 45 years
      (inclusive). The study aimed to evaluate the PK, safety, tolerability and immunogenicity of
      Abcertin compared with EU-sourced Cerezyme when administered as a single dose.
    
  